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Metabolic profile in patients with newly 
diagnosed bipolar disorder and their unaffected 
first-degree relatives
Klara Coello1,2* , Maj Vinberg1,2, Filip K. Knop2,3, Bente K. Pedersen2,4, Roger S. McIntyre5, Lars V. Kessing1,2 
and Klaus Munkholm1
Abstract 
Objective: The prevalence of metabolic syndrome and insulin resistance is twice as high in patients with bipolar 
disorder compared with the general population, and possibly associated with a disabling illness trajectory of bipo-
lar disorder, an increased risk of cardiovascular disease and premature death. Despite these detrimental effects, the 
prevalence of metabolic syndrome and insulin resistance in patients newly diagnosed with bipolar disorder and their 
unaffected first-degree relatives is largely unknown.
Methods: In a cross-sectional study of 206 patients with newly diagnosed bipolar disorder, 50 of their unaffected 
first-degree relatives and 109 healthy age- and sex-matched individuals, we compared the prevalence of metabolic 
syndrome and insulin resistance (HOMA-IR). In patients with bipolar disorder, we further investigated illness and medi-
cation variables associated with the metabolic syndrome and insulin resistance.
Results: Higher rates of metabolic syndrome (odds ratio = 3.529, 95% CI 1.378–9.041, P = 0.009) and levels of insulin 
resistance (B = 1.203, 95% CI 1.059–1.367, P = 0.005) were found in patients newly diagnosed with bipolar disorder, 
but not in their unaffected first-degree relatives compared with matched healthy individuals (data adjusted for sex 
and age). Most patients with bipolar disorder (94.7%) were diagnosed within the preceding 2 years, and the average 
illness duration, defined as time from first mood episode, was 10 years.
Conclusion: Our findings of elevated prevalence of metabolic syndrome and insulin resistance in patients with 
newly diagnosed bipolar disorder highlight the importance of screening for these conditions at an early stage to 
employ adequate and early care reducing the risk of cardiovascular disease and premature death.
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Introduction
Bipolar disorder (BD) is associated with a decreased 
life expectancy of 8–12 years (Laursen et al. 2013; Kess-
ing et al. 2015) with cardiovascular disease (CVD) being 
the leading cause of excess mortality (Osby et  al. 2001). 
Patients with BD have increased risk of developing CVD 
compared with the general population (Goldstein 2017), 
and the American Heart Association recognizes BD in 
youth as a moderate-risk condition for early CVD and 
accelerated atherosclerosis (Goldstein et al. 2015). Meta-
bolic syndrome (metS) constitutes a cluster of CVD risk 
factors consisting of abdominal obesity, diabetes and/
or raised fasting plasma glucose, dyslipidemia and high 
blood pressure (Alberti et  al. 2006). In general, pres-
ence of metS doubles the risk of CVD related mortality 
(Alberti et al. 2006). In patients with BD the prevalence 
of metS is doubled compared with the general popula-
tion, an observation that appears to be a global phenom-
enon (Vancampfort et al. 2013).
Insulin resistance and central obesity are central com-
ponents of metS (Alberti et  al. 2006). Further, insulin 
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resistance, metS and type 2 diabetes may separately be 
associated with adverse outcomes in patients with BD 
such as rapid cycling, treatment resistance to BD, and 
progression into a chronic illness course (Calkin et  al. 
2015; McIntyre et  al. 2010; Cairns et  al. 2018). Over-
weight and obesity have also been associated with 
increased severity of bipolar depression and a decreased 
treatment response that diminishes with increasing body 
mass index (BMI) (Kemp et al. 2010; Calkin et al. 2009). 
Similarly, the number and frequency of illness episodes 
seem to be increased in dysglycemic patients with BD 
compared with euglycemic patients (Calkin et  al. 2015) 
and dysglycemia has been suggested to constitute a mod-
erator of illness progression in BD (Mansur et al. 2016).
Despite robust evidence of the detrimental effects 
of metabolic comorbidity in BD, it is largely unknown 
whether risk factors for metS are present in newly diag-
nosed BD. Three prior case–control studies of metS in a 
small number of patients newly diagnosed with BD did 
not find a higher prevalence of metS compared with 
healthy individuals (Guha et al. 2014; Taylor et al. 2010; 
Wulsin et  al. 2018). However, due to small sample sizes 
(n = 23–56) a true difference in prevalence may pos-
sibly have been overlooked. One of these studies (Guha 
et  al. 2014), additionally, is the only case–control study 
of insulin resistance in patients newly diagnosed with 
BD, and they found higher insulin resistance index but 
not higher rates of metS in medication free, newly diag-
nosed patients with BD (Guha et al. 2014). However, the 
age of the participants (43.2 ± 10.6 years) suggested that 
the patients with BD were in a relatively late illness stage 
(Guha et  al. 2014). Apart from one small study observ-
ing decreased high-density lipoprotein (HDL) cholesterol 
in first-degree unaffected relatives of patients with BD 
(Sobczak et al. 2004), it is largely unknown whether risk 
factors for metS, are present in unaffected first-degree 
relatives of BD.
Aims of the study
The aims of the present study were: (I) to compare the 
prevalence of metS and levels of insulin resistance, as 
well as individual risk factors for metS and insulin resist-
ance between patients with newly diagnosed BD and 
their unaffected first-degree relatives with healthy indi-
viduals without personal or first-degree family history of 
affective disorder; and (II) to determine to what extent 
illness and medication variables in patients with BD were 
associated with metS and insulin resistance.
We hypothesized that the prevalence of metS and insu-
lin resistance was higher in patients with newly diag-
nosed BD and—to a lesser degree—in their unaffected 
first-degree relatives compared with healthy individuals 
without a family history of psychiatric disorders.
Materials and methods
Study design
The present report is a cross-sectional investigation of 
baseline data from the ongoing, longitudinal Bipolar 
Illness Onset Study (BIO), which aims to identify com-
posite biomarkers for BD (Kessing et  al. 2017). Partici-
pants were recruited from June 2015 to September 2017. 
The study protocol was approved by the Committee on 
Health Research Ethics of the Capital region of Denmark 
(protocol No. H-7-2014-007) and the Danish Data Pro-
tection Agency, Capital Region of Copenhagen (RHP-
2015-023). Written informed consent was provided by all 
participants. The study complied with the Declaration of 
Helsinki principles (Seoul, October 2008).
Participants
Patients with bipolar disorder
Patients were recruited from the Copenhagen Affec-
tive Disorder Clinic that covers the greater Copenhagen 
area of 1.6 million inhabitants (The Capital Region). All 
patients having a first episode of (hypo)mania or newly 
diagnosed with BD were routinely invited to participate 
in the study by the clinicians in the Copenhagen Affec-
tive Disorder Clinic (Kessing et al. 2017). Inclusion crite-
ria were an ICD-10 diagnosis of a single manic episode or 
BD and age 15–70 years. Exclusion criteria included hav-
ing an organic BD secondary to brain injury. The patients 
received treatment as usual without interference from 
study investigators.
Unaffected first‑degree relatives
Siblings and children of the included patients with BD 
were invited to participate upon consent by the par-
ticipating patient. Inclusion criteria were being a first-
degree relative of an included patient with BD and age 
15–40 years. Exclusion criteria included ICD-10 diagno-
ses of substance abuse, psychotic illnesses and mood dis-
orders. We did not restrict the number of participating 
unaffected first-degree relatives per patient with BD as 
we adjusted for familial relationship in our analysis.
Healthy individuals
Age and sex-matched healthy individuals were recruited 
on random days among blood donors from the Blood 
Bank at Rigshospitalet, Copenhagen, Denmark. The 
inclusion criterion was age 15–70 years. Exclusion crite-
ria were a personal or first-degree family history of psy-
chiatric disorders that had required treatment.
Clinical assessments
In the Copenhagen Affective Disorder Clinic, a special-
ist in psychiatry diagnosed patients with BD according to 
ICD-10 and classified them as type I or type II according 
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to DSM-5 at the beginning of a two-year treatment 
program.
All participants were assessed by a medical doctor or a 
psychologist trained in diagnosing BD. The clinical diag-
nosis of BD was confirmed using the semi-structured 
interview: the Schedules for Clinical Assessment in Neu-
ropsychiatry (SCAN) (Wing et  al. 1990). Diagnosis of 
the current affective state was based on ICD-10 criteria. 
Severity of depressive and manic symptoms was assessed 
using the Hamilton Depression Rating Scale-17 items 
(HAMD-17) (Hamilton 1960) and the Young Mania Rat-
ing Scale (YMRS) (Young et al. 1978) respectively. Sleep 
quality was assessed using the Pittsburgh Sleep Qual-
ity Index (PSQI) (Buysse et al. 1989) and physical activ-
ity was assessed using the International Physical Activity 
Questionnaire (IPAQ) (Craig et  al. 2003), which were 
both administered at the day of assessment. Medication, 
alcohol intake and smoking habits were recorded. Alco-
hol intake was stratified into low intake (0–4 units per 
week), moderate intake (5–13 units per week) and high 
intake (> 13 units per week).
Absence of lifetime psychiatric morbidity defined by 
ICD-10 was confirmed for healthy individuals whereas 
psychiatric morbidity of F34 and higher (e.g., cyclothy-
mia, anxiety and personality disorders) according to 
ICD-10 were registered for unaffected relatives.
Anthropometric assessment
After a 10-min rest blood pressure was measured in a sit-
ting position using a calibrated automatic sphygmanom-
eter (Microlife BP A3 plus) at the same day as the clinical 
assessment. Further, waist circumference was measured 
at the midpoint between the lowest rib and the iliac 
crest in an upright position to the nearest millimeter as 
described in the World Health Organisation’s guidelines 
(Cornier et al. 2011). Lightly dressed and without shoes, 
height was measured to the nearest millimeter on a rigid 
stadiometer and weight was measured to the nearest 
0.1 kg using a calibrated floor scale (Kern MPE  PM®).
Laboratory methods
Fasting blood samples were collected in a resting state 
between 7.30 AM and 10 AM at the same day as the 
clinical assessment. Five milliliters of blood was drawn 
by venipuncture into an EDTA containing vacuum tube 
 (Vacuette®) and within 30 min centrifuged at 1590 g and 
4  °C for 15  min. Plasma was aliquoted into  Eppendorf® 
tubes and kept frozen at − 80  °C until P-Insulin was 
assayed. Plasma/serum concentrations of glucose, tri-
glyceride, HbA1c and HDL cholesterol were measured 
using standard laboratory routine assays. Blood sampling 
and all aspects of laboratory processing were done at the 
Department of Clinical Biochemistry, Rigshospitalet, by 
laboratory specialists blinded with respect to participant 
status.
Determination of metabolic syndrome, type 2 diabetes 
and insulin resistance
Metabolic syndrome was defined according to the Inter-
national Diabetes Federation 2006 criteria (Alberti et al. 
2006). Participants were considered having type 2 dia-
betes if they met at least one of the following three cri-
teria: a diagnosis of type 2 diabetes, use of antidiabetic 
treatment (without other indication), and/or having a 
hemoglobin A1c (HbA1c) level of 48 mmol/mol or above. 
Insulin resistance was calculated from fasting plasma glu-
cose and insulin using the homeostasis model assessment 
of insulin resistance (HOMA-IR) (HOMA-IR = (plasma 
glucose (mmol/L) × plasma insulin (mIU//L)/22.5 (Her-
mans et  al. 1999)). To convert insulin from pmol/L to 
µIU/ml = mIU/L we divided with six, which has been 
found to be the most appropriate conversion factor 
(Larsen et al. 2017).
Statistical analyses
Descriptive data were analyzed by Chi square tests for 
categorical data and by Student’s t test and Mann–Whit-
ney U tests for two independent groups for continuous 
data, according to whether assumptions of normal distri-
bution were met or not. Continuous data were presented 
as median and quartiles if assumptions of normal distri-
bution were not met.
For illustrative purposes, we first compared prevalence 
of metS and levels of insulin resistance in an unadjusted 
generalized mixed effect model (categorical outcome) 
and a linear mixed effect model (continuous outcome), 
respectively, with familial relationship as random effect, 
to account for the correlation between family-related 
individuals. In a second model we adjusted for age and 
sex and as a third fully adjusted model we further added 
smoking status and alcohol intake as covariates.
In analyses among patients with BD we explored the 
associations between medication and illness characteris-
tics and metS and insulin resistance, respectively, in sepa-
rate models to retain sufficient statistical power. In these 
models, illness duration, BD type (I or II), current medi-
cation type in the form of lithium (yes/no), antipsychotics 
(yes/no), antidepressants (yes/no) and antiepileptics (yes/
no) and, finally, receiving psychotropics with metabolic 
adverse effects were entered as predictors along with the 
covariates age and sex. All daily psychotropic medication 
except for lamotrigine and aripiprazole were considered 
psychotropics with metabolic adverse effects (Abosi et al. 
2018). The category ‘not receiving psychotropics with 
metabolic adverse effect’ included patients not receiv-
ing psychotropic medication as well as patients receiving 
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lamotrigine, aripiprazole or low dose quetiapine (i.e., not 
exceeding 50  mg daily). Illness duration was defined as 
time from first episode (depressive, hypomanic, manic 
or mixed episode). In a separate analysis we explored the 
association between demographic- and lifestyle variables 
and metS and insulin resistance among patients with BD, 
with these as dependent variables, and age, sex, smoking 
status, alcohol intake, sleep quality and physical activity 
as independent variables.
For all parametric tests, insulin resistance was trans-
formed by the natural logarithm. Results are presented 
as back transformed values with a parameter estimate 
B, expressing the ratio between increments in independ-
ent variables. In the generalized linear mixed models, the 
model estimate, logit, was back transformed and pre-
sented as odds ratios. All model assumptions were met. 
The level of statistical significance was set at p < 0.05. Sta-
tistical analyses were performed using R version 3.3.2 and 
SPSS version 22.
Results
Demographic and clinical characteristics
We included 206 patients with BD, 50 of their unaffected 
relatives and 109 healthy individuals. Five patients with 
BD were Asian, five patients with BD were of mixed 
Asian and Caucasian ancestry and the remaining par-
ticipants were Caucasian. Demographic and clinical vari-
ables of the study participants are presented in Table 1. 
Unaffected relatives were from 39 distinct families as 11 
patients with BD had two of their unaffected relatives 
included. The patients with BD and healthy individuals 
were comparable in age (median [interquartile range] age 
29.5 [24–37] vs. 28 [24–36.5] years, P = 0.8). Sex distri-
bution in the three groups (patients with BD, unaffected 
relatives, healthy individuals) was similar. The unaffected 
first-degree relatives were younger than healthy individu-
als (P = 0.024). Healthy individuals had higher education 
level than patients with BD (P = 0.001), whereas educa-
tion level did not differ between unaffected relatives and 
healthy individuals. Levels of activity, measured in meta-
bolic equivalent minutes, were lower in patients with BD 
compared with healthy individuals (P = 0.013) and did 
not differ between unaffected relatives and healthy indi-
viduals (P = 0.9). More patients with BD and unaffected 
relatives reported sleep disturbances than healthy indi-
viduals (P < 0.001 and P = 0.001, respectively). Patients 
with BD had a lower weekly alcohol intake than healthy 
individuals (P < 0.001), whereas alcohol units per week 
were similar in unaffected relatives and healthy indi-
viduals (P = 0.1). Smoking was more common among 
patients with BD and their unaffected relatives compared 
to healthy individuals (Chi squared < 0.001). Among the 
patients with BD, 81.1% (n = 167) were diagnosed within 
the preceding year; additionally, 13.6% (n = 28) were 
diagnosed within the last 2  years, whereas the remain-
ing 5.4% (n = 11) were diagnosed within the preceding 
7 years.
Metabolic syndrome in patients with bipolar disorder, their 
unaffected first‑degree relatives and healthy individuals
As depicted in Fig. 1, 15.0% of patients with BD, 6.0% of 
their unaffected first-degree relatives and 5.5% of healthy 
individuals met criteria for metS. In the unadjusted anal-
ysis, the prevalence of metS was higher in patients with 
BD (B = 3.041, 95% CI 1.227–7.535, P = 0.016) but not in 
their unaffected relatives (B = 1.096, 95% CI 0.263–4.570, 
p = 0.9) compared with healthy individuals (Table  2, 
model 1a). Adjusted for age and sex, patients with BD 
had 3.5 higher risk of having metS than healthy individu-
als (B = 3.529, 95% CI 1.378–9.041, P = 0.009), whereas 
no statistically significant difference was found between 
unaffected relatives and healthy individuals (B = 1.472, 
95% CI 0.334–6.497, P = 0.6) (Table  2, model 1b). In a 
fully adjusted model controlling additionally for smoking 
status and alcohol use, however, the observed difference 
in metS between the groups was no longer statistically 
significant (Table  2, model 1c). In a comparable model, 
there was no statistical difference in the prevalence of 
metS between unaffected relatives and patients with BD 
(B = 0.417, 95% CI 0.118–1.467, P = 0.2). Repeating the 
main analysis of metS between groups adjusted for age 
and sex, excluding the two patients with BD with type 2 
diabetes, did not change the results (B = 3.250, 95% CI 
1.270–8.319, P = 0.009).
Insulin resistance in patients with bipolar disorder, their 
unaffected first‑degree relatives and healthy individuals
Measurements of insulin were missing in three 
patients, one unaffected relative and three healthy indi-
viduals, consequently these seven participants were 
only included in analyses of metS but not of insulin 
resistance. As shown in Fig.  1 the median [interquar-
tile range] of insulin resistance (HOMA-IR) was 2.06 
[1.44–3.25] in patients with BD, 2.10 [1.59–2.63] in 
unaffected relatives and 1.73 [1.35–2.42] in healthy 
individuals. In the unadjusted model, levels of insu-
lin resistance were 20.3% higher in patients with BD 
compared with healthy individuals (B = 1.203, 95% CI 
1.058–1.367, P = 0.005) while no difference was found 
between unaffected relatives and healthy individu-
als (Table 2, model 2a). After adjusting for age and sex 
the levels of insulin resistance remained elevated in 
patients with BD compared with healthy individuals 
(B = 1.203, 95% CI 1.059–1.367, P = 0.005) (Table  2, 
model 2b). In a comparable model, there was no statis-
tical difference in levels of insulin resistance between 
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patients with BD and unaffected relatives (B = 1.125, 
95% CI 0.958–1.321, P = 0.1). In a fully adjusted model 
controlling additionally for smoking status and alcohol 
use, however, the observed difference in insulin resist-
ance between the groups was no longer statistically 
significant (Table  2, model 2c). In a post hoc analysis, 
we added waist circumference as a covariate in the fully 
adjusted model and it did not alter the findings, how-
ever, waist circumference was associated with insulin 
resistance (B = 1.023, 95% CI 1.018–1.028, P ≤ 0.001)).
Table 1 Demographic and clinical variables in patients with bipolar disorder (BD), their unaffected first-degree relatives 
(UR) and healthy individuals (HC)
Continuous variables are presented as median [interquartile range]. Categorical variables are presented as n (%). HOMA-IR the Homeostasis model assessment of 
insulin resistance, IPAQ International Physical Activity Questionnaire, MET-minutes metabolic equivalent minutes, PSQI: Pittsburgh Sleep Quality Index, HAMD-17 
17-item Hamilton Depression Rating Scale, YMRS Young Mania Rating Scale, BD I and BD II Bipolar Disorder type I and II, respectively, N.A. not available
a Untreated bipolar disorder was defined as time from first manic, hypomanic or mixed episode to time of diagnosing bipolar disorder
BD UR HC
N 206 50 109
Metabolic syndrome 31 (15) 3 (6) 6 (5.5)
Insulin resistance (HOMA-IR) 2.06 [1.44–3.25] 2.10 [1.59–2.63] 1.73 [1.35–2.42]
Age (years) 29.5 [24–37] 26.5 [22–31.3] 28 [24–36.5]
Sex (% female) 126 (61.2) 25 (50) 66 (60.6)
Education (years total) 15 [12.5–16] 15 [13–17] 15.5 [14.5–17]
Number of smokers (%) 95 (46.1) 13 (27.1) 10 (9.3)
Alcohol, units per week 2 [0–7] 2 [1–8] 5 [2–7]
Exercise (IPAQ, MET-minutes per week) 1680 [698–3051] 2373 [754–5270] 2040 [1160–4320]
Sleep disturbance (PSQI total score) 9 [6–13] 5.5 [3.8–8.3] 4 [2–6]
HDRS-17 9 [5–15] 2 [0–4] 1 [0–2]
YMRS 2 [0–6] 0 [0–2] 1 [0–2]
BD I 75 (34.4) – –
BD II 127 (61.7) – –
Single manic episode 4 (1.9) – –
Age of onset 17 [14–21] – –
Illness duration (years) 10 [6–16] – –
Untreated bipolar disorder (years)a 5 [1–11] – –
Manic episodes 0 [0–1] – –
Hypomanic episodes 4 [2–15] – –
Depressive episodes 6 [3–15] – –
Mixed episodes 0 [0–0] – –
Total affective episodes 12.5 [6–30] – –
Hospitalizations 0 [0–1] – –
Current affective episode
Remission 124 (60.2) – –
Mild/moderate depressive episode 42 (20.4) – –
Severe depressive episode 6 (2.9) – –
Mixed episode 10 (4.9) – –
Hypomanic episode 17 (8.3) – –
Manic episode 2 (1) – –
N.A. 2 (1) – –
Medication
No psychotropic medication 29 (14.1) – –
Lithium treatment 74 (35.9) – –
Antiepileptic treatment 108 (52.4) – –
Antidepressant treatment 55 (26.7) – –
Antipsychotic treatment 67 (32.5) – –
Psychotropic medication with metabolic adverse effects 127 (61.7) – –
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We repeated our main analysis of insulin resistance 
adjusted for age and sex, excluding the two patients with 
BD with type 2 diabetes and this did not change the 
results (B = 1.199, 95% CI 1.055–1.362, P = 0.005).
Individual components of the metabolic syndrome 
and insulin resistance
Levels of the individual components of the metS and 
insulin resistance, respectively, are shown in Table  3. 
Patients with BD had a larger waist circumference 
(P = 0.008) than healthy individuals and in explora-
tive sex-specific analyses female patients with BD had a 
larger median [interquartile range] waist circumference 
than healthy female individuals (83 [76–90] cm vs. 78 
[74–85] cm P = 0.014) whereas male patients with BD 
did not differ from healthy male individuals (91 [84–104] 
cm vs. 88 [82–94] cm P = 0.7). Compared with healthy 
individuals, patients with BD had higher levels of triglyc-
erides (P < 0.001), fasting glucose (P = 0.047) and fasting 
insulin (P = 0.009), and lower levels of HDL cholesterol 
(P = 0.001) and systolic blood pressure (P = 0.004). Unaf-
fected relatives had lower levels of HDL cholesterol than 
healthy individuals (P = 0.017), whereas the other com-
ponents did not differ between these two groups.
Association between illness‑ and medication variables 
and metabolic syndrome and insulin resistance 
among patients with bipolar disorder
Illness duration (B = 0.637, 95% CI 0.409–0.998, 
P = 0.047) was negatively associated with metS (Table 4, 
model 1). No association between individual psycho-
tropic medication types and metS was observed. Lithium 
treatment was positively associated with insulin resist-
ance (B = 1.242, 95% CI 1.045–1.478, P = 0.014), while 
no association was observed between illness duration or 
other individual types of psychotropic medication and 
insulin resistance (Table  4, model 2). When grouping 
medication according to their likely metabolic impact, 
treatment with psychotropic medication with metabolic 
adverse effects was associated with higher insulin resist-
ance (B = 1.298, 95% CI 1.088–1.550, P = 0.004). How-
ever, no association was found between treatment with 
psychotropic medication with metabolic adverse effects 
and metS (B = 2.325, 95% CI 0.873–6.194, P = 0.09). No 
Fig. 1 a Clustered bar chart of metabolic syndrome and b box plot of insulin resistance in patients with newly diagnosed bipolar disorder (BD), 
their unaffected first-degree relatives (UR) and healthy individuals (HC). The lower and upper hinges in the box plot correspond to the first and 
third quartiles and the upper and lower whiskers extend from the hinge to the largest and lower value, respectively, no further than 1.5 times the 
interquartile range from the hinge. Data beyond the end of the whiskers are plotted individually. MetS: metabolic syndrome; HOMA-IR: homeostasis 
model assessment of insulin resistance
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association was found between BD subtype and metS or 
insulin resistance.
Association between demographic‑ and lifestyle 
variables and metabolic syndrome and insulin resistance 
among patients with bipolar disorder
There was no statistically significant association between 
metS and sex, smoking status, alcohol intake, sleep qual-
ity or physical activity among patients with BD. A mod-
erate alcohol intake was associated with lower insulin 
resistance compared with a low alcohol intake in patients 
with BD (B = 0.868, 95% CI 0.763–0.988, P = 0.033) and 
male sex was associated with higher insulin resistance 
(B = 1.174, 95% CI 1.037–1.328, P = 0.011). Smoking sta-
tus, sleep quality and physical activity were not associ-
ated with insulin resistance in patients with BD.
Discussion
Main results
We found a higher prevalence of metS and greater degree 
of insulin resistance in 206 newly diagnosed bipolar 
patients with a median age of 29.5 [24–37] years, but not 
in the 50 unaffected first-degree relatives, compared with 
109 age and sex-matched healthy individuals. Consider-
ing smoking status and alcohol use in an adjusted model, 
however, the observed difference between patients with 
bipolar disorder and healthy individuals was no longer 
statistically significant. Comparing the individual compo-
nents of the metS and insulin resistance between groups 
revealed an adverse metabolic profile among patients 
with newly diagnosed BD who had a larger waist circum-
ference, more dyslipidemia with higher levels of triglyc-
erides and lower levels of HDL cholesterol and higher 
levels of fasting glucose and insulin compared with 
healthy individuals. The unaffected relatives had lower 
levels of HDL cholesterol than healthy individuals. In 
analyses among patients with BD, treatment with lithium 
as well as treatment with medication with adverse meta-
bolic effects were associated with higher levels of insulin 
resistance, whereas illness duration was negatively asso-
ciated with metS.
Comparison to other case–control studies in patients 
with newly diagnosed bipolar disorder
Three previous studies investigated metS in patients with 
newly diagnosed BD compared with healthy individuals 
(Guha et al. 2014; Taylor et al. 2010; Wulsin et al. 2018) 
and one of these additionally assessed insulin resistance 
(Guha et al. 2014). Unlike our study, these prior studies 
did not include analyses adjusted for alcohol and smok-
ing. Two of these studies found no difference in preva-
lence of metS in patients newly diagnosed with BD 
compared with healthy individuals (Guha et  al. 2014; 
Taylor et al. 2010). However, in the study by Guha et al.
(2014) including 55 patients with BD and 25 controls, 
the high mean age 43.2 years (SD: 10.6) of patients with 
BD indicated that patients were possibly in a later ill-
ness stage compared with our population of newly diag-
nosed patients with BD. Furthermore, their population 
of patients with BD and healthy individuals had more 
central obesity than participants in our study sample. 
The study by Taylor et al. (2010) included only 24 newly 
diagnosed patients with BD, and may have been under-
powered to detect differences between groups. The third 
case–control study (Wulsin et al. 2018) found comparable 
rates of metS to our findings and the lack of statistically 
Table 2 Metabolic syndrome and  insulin resistance 
in patients with bipolar disorder (BD) and their unaffected 
first-degree relatives (UR) compared with  healthy 
individuals (HC)
Model 1: Generalized linear mixed model with metabolic syndrome as the 
dependent variable. B represents odds ratios
Model 2: Linear mixed model with insulin resistance as the dependent variable. 
B represents back transformed beta values
Model B 95% CI P value
1 Metabolic syndrome
a BD vs. HC 3.041 1.227–7.535 0.016
UR vs. HC 1.096 0.263–4.570 0.9
b Male vs. female sex 1.954 1.142–2.168 0.059
Age 1.574 1.142–2.168 0.056
BD vs. HC 3.529 1.378–9.041 0.009
UR vs. HC 1.472 0.334–6.497 0.6
c Male vs. female sex 2.117 0.998–4.494 0.051
Age 1.580 1.137–2.197 0.006
BD vs. HC 1.918 0.669–5.498 0.2
UR vs. HC 1.108 0.027–0.432 0.9
No smoking 0.332 0.151–0.730 0.006
High vs. low alcohol intake 1.107 0.369–3.318 0.9
Moderate vs. low alcohol intake 0.739 0.317–1.727 0.5
2 Insulin resistance
a BD vs. HC 1.203 1.058–1.367 0.005
UR vs. HC 1.092 0.0910–1.311 0.3
b Male vs. female sex 1.095 0.977–1.238 0.1
Age 0.996 0.989–1.002 0.2
BD vs. HC 1.203 1.059–1.367 0.005
UR vs. HC 1.069 0.889–1.287 0.5
c Male vs. female sex 1.129 1.001–1.273 0.048
Age 0.995 0.982–1.002 0.2
BD vs. HC 1.129 0.982–1.234 0.1
UR vs. HC 1.019 0.842–1.234 0.8
Smoking 1.113 0.974–1.271 0.1
High vs. low alcohol intake 0.857 0.704–1.044 0.1
Moderate vs. low alcohol intake 0.905 0.796–1.029 0.1
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significance may have been due to lack of power owing 
to a relatively small group of healthy individuals (n = 56). 
Further, these three studies of metS in patients with 
newly diagnosed BD all assessed metS using the National 
Cholesterol Education Program adult treatment panel III 
(ATPIII) definition, whereas we used the International 
Diabetes Federation’s criteria, which are the most com-
monly used criteria in Europe with cut-offs for central 
obesity specific for populations of Europid origin. The 
ATPIII definition can be met without having central obe-
sity and the cut-off for central obesity for populations of 
North American origin is more liberal than the Interna-
tional Diabetes Federation’s criteria (Kaur 2014). If these 
studies had used the International Diabetes Federation’s 
criteria it is possible that they had found similar results 
to ours (e.g. in the study by Guha et al. (2014) only seven 
Table 3 Individual components of the metabolic syndrome and insulin resistance in patients with bipolar disorder (BD) 
and their unaffected first-degree relatives (UR) compared with healthy individuals (HC)
HDL high density lipoprotein, MmHg millimeters of mercury. Continuous variables are presented as median [interquartile range]
BD1 UR2 HC3 P‑value
N 206 50 109
Waist circumference (cm) 85 [78–94] 79 [74–89] 82 [75–90] 0.0081−3
0.42−3
Triglycerides (mmol/L) 0.94 [0.70–1.39] 0.77 [0.66–1.03] 0.76 [0.61–0.97] < 0.0011−3
0.42−3
HDL cholesterol (mmol/L) 1.49 [1.24–1.83] 1.52 [1.29–1.79] 1.68 [1.35–1.94] 0.0011−3
0.0172−3
Systolic blood pressure (mmHg) 120 [111–129] 124 [114–135] 124 [116–136] 0.0041−3
0.92−3
Diastolic blood pressure (mmHg) 77 [70–83] 78 [70–84] 77 [72–85] 0.11−3
0.32−3
Fasting plasma glucose (mmol/L) 5.0 [4.8–5.4] 5.1 [4.8–5.4] 5.0 [4.7–5.2] 0.0471−3
0.12−3
Type 2 diabetes 2 (0.9) 0 0
Insulin (pmol/L) 55.8 [39.7–84.8] 56.8 [42.0–69.9] 48.9 [38.5–63.6] 0.0091−3
0.12−3
Table 4 Metabolic syndrome and insulin resistance in patients with bipolar disorder
Model 1: Separate generalized linear mixed models of metabolic syndrome (a–g) in patients with BD, adjusted for age and sex. B represents odds ratios
Model 2: Separate linear mixed models of insulin resistance (a–g) in patients with BD, adjusted for age and sex. B represents back transformed beta values
BD I and BD II: Bipolar Disorder type I and II, respectively. aIllness duration was defined as time from first episode (depressive, hypomanic, manic or mixed episode)
Model B 95% CI P‑value
1 Metabolic syndrome
a Illness  durationa 0.637 0.409–0.993 0.047
b BD type I vs. type II 0.769 0.345–1.705 0.5
c Lithium 0.993 0.438–2.252 1.0
d Antipsychotics 0.845 0.361–1.981 0.7
e Antiepileptics 0.782 0.350–1.748 0.5
f Antidepressants 2.517 1.717–3.691 0.7
g Medication with metabolic adverse effects 2.325 0.873–6.194 0.1
2 Insulin resistance
a Illness  durationa 0.987 0.974–1.000 0.056
b BD type I vs. type II 0.891 0.745–1.065 0.2
c Lithium 1.242 1.045–1.478 0.014
d Antipsychotics 1.082 0.903–1.294 0.4
e Antiepileptics 0.874 0.736–1.040 0.1
f Antidepressants 1.075 0.882–1.310 0.3
g Medication with metabolic adverse effects 1.298 1.088–1.550 0.004
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out of 55 patients newly diagnosed with BD fulfilled the 
ATPIII criteria). Similarly to the results by Guha et  al. 
(2014) we found elevated levels of insulin resistance in 
patients with newly diagnosed BD, although as discussed 
above, patients with BD in our study were substantially 
younger than patients with BD in the study by Guha et al. 
(2014).
Illness‑ and medication variables
In patients with BD we observed a negative associa-
tion between illness duration and metS while extant 
research appears to have indicated a lack of such an 
association (Vancampfort et  al. 2013). However, the 
confidence interval for the estimate of the association 
was wide and although we adjusted the analysis for age 
and sex it cannot be excluded that the finding is due to 
residual confounding. We did not replicate previous 
findings of treatment with antipsychotics being associ-
ated with increased prevalence of metS (Vancampfort 
et al. 2013), but found treatment with lithium associated 
with increased levels of insulin resistance. However, the 
observed effect was rather small and due to the observa-
tional design and the limitations in estimating effects of 
single treatment categories in patients receiving several 
types of medications, caution should be observed when 
interpreting this finding. Given those limitations, it may 
be more meaningful to consider medication in their 
capacity to induce metabolic changes, when estimating 
the association between medication and metS or insulin 
resistance. Using this approach, we found that patients 
using medication with metabolic side effects had more 
insulin resistance, but not a higher risk of metS, com-
pared with patients that did not use such medication. The 
association between medication with capacity to induce 
metabolic changes and metS did not reach statistically 
significance, however, this may be due to the relatively 
low power of the analysis, and overall, our results point 
to medication as an important risk factor for metS.
In accordance with Calkin et al.’s (2015) findings we did 
not find association between the type of BD and insulin 
resistance. Finally, the type of BD was neither associated 
with metS.
Individual components of the metabolic syndrome 
and insulin resistance
Patients with BD had larger waist circumferences than 
healthy individuals. Robust epidemiological evidence 
associates central obesity with increased overall mortal-
ity as well as excess death caused by CVD (Cornier et al. 
2011; Pischon et al. 2008) and, notably, the median waist 
circumference of 83  cm in our female patients with BD 
exceeded the cut-off for central obesity defined by the 
International Diabetes Federation (≥ 80  cm) (Alberti 
et  al. 2006), while waist circumference medians of male 
patients with BD and healthy individuals of both sexes 
were below the threshold for central obesity. We also 
found an adverse lipid profile in patients with BD with 
lower levels of HDL cholesterol and higher levels of tri-
glycerides similar to recent findings in patients with BD 
compared with healthy individuals (Wulsin et  al. 2018). 
The only individual component of metS not differing in 
patients with BD compared with healthy individuals was 
the systolic blood pressure which align with findings of 
a recent meta-analysis of metS and severe mental illness, 
where the risk of metS and all its individual components 
except for hypertension were elevated in patients with 
BD (Vancampfort et al. 2015).
Fasting insulin levels were higher in patients with BD 
compared with healthy individuals, supporting the find-
ings by Guha et  al. (2014). In contrast to that study, we 
also detected higher levels of fasting glucose in patients 
with newly diagnosed BD compared with healthy individ-
uals, although the levels were within normal ranges in all 
three groups. Only mild non medicated type 2 diabetes is 
allowed among blood donors and we therefore repeated 
our main analyses of metS and insulin resistance exclud-
ing the two patients with BD with comorbid type 2 dia-
betes. This, however, did not alter the results of our main 
analyses, which we find to be most correct, as the two 
patients with BD were not in treatment for type 2 diabe-
tes and were unaware of having type 2 diabetes at time 
of assessment, thus not treated, which could happen for 
blood donors as well.
Possible predictors of metabolic syndrome and insulin 
resistance in patients with bipolar disorder
In the current study, patients with BD differed further 
from healthy individuals in regard to active smoking (Sun 
et al. 2012), alcohol intake (Alkerwi et al. 2009), activity 
level (Zhang et al. 2017) and sleep disturbances (Pulido-
Arjona et  al. 2018), which are major predictors of metS 
and insulin resistance. We found that 46% of the patients 
with BD were smokers, which is more than twice the 
prevalence of the Danish general population (SST 2017) 
versus 27% of their unaffected relatives and 9% of their 
healthy individuals. Smoking cessation increases the lev-
els of HDL cholesterol (März et  al. 2017) and has been 
shown to reduce the risk of metS (Sun et  al. 2012). We 
found smoking to be associated with metS in our over-
all analyses (Sun et al. 2012), whereas we found no effect 
of activity level and sleep disturbances in patients with 
bipolar disorder. Further, in these models, we did not find 
associations between insulin resistance level and smok-
ing, activity level and sleep disturbances, respectively. 
However, interpretation of these analyses should be 
made with caution as we are comparing relatively small 
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subsamples of patients with BD. In the present study, 
patients with newly diagnosed BD had a lower alcohol 
intake than healthy individuals, and whereas alcohol in 
small amounts seems protective of metS high alcohol 
intake increases the risk of metS (Alkerwi et  al. 2009). 
We did not find an association between metS and alco-
hol neither in comparison of the three groups or within 
patients with BD. However, alcohol intake was relatively 
low in all three groups in the present study suggesting a 
minor role of alcohol in the current observations. Our 
finding of higher insulin resistance level among patients 
with low alcohol intake compared with patients with 
moderate alcohol intake was unexpected. However, many 
patients with BD have had an increased alcohol intake 
the preceding months before initiating treatment in the 
Copenhagen Affective Disorder Clinic and were encour-
aged to restrict or completely avoid alcohol for the ini-
tial 3  months in the clinic. A preceding large alcohol 
intake would not be captured in our measure, thus our 
finding of a negative association between higher alcohol 
intake and lower prevalence of insulin resistance among 
patients with BD, should be interpreted with caution. 
Patients with BD were less physically active than healthy 
individuals. This may contribute to the present findings 
and could be due to symptoms related to BD but may also 
be related to the use of sedative medication. The lower 
level of activity could likely contribute to the lower levels 
of HDL cholesterol observed in the present study, such 
as observed in other studies of patients with BD (Chen 
et  al. 2017). Finally, sleep disturbances in young adults 
are associated with dysmetabolism such as higher fast-
ing glucose levels and triglyceride levels and lower levels 
of HDL cholesterol (Pulido-Arjona et al. 2018) and were 
more prevalent in patients with BD and in their unaf-
fected first-degree relatives in the current study.
Metabolic syndrome and insulin resistance in unaffected 
first‑degree relatives
Studying unaffected relatives may help to clarify if there 
is a common shared pathophysiology of BD and type 2 
diabetes and/or CVD (de Melo et al. 2017; SayuriYama-
gata et  al. 2017). Apart from lower levels of HDL cho-
lesterol in unaffected relatives compared with healthy 
individuals, our findings did not indicate dysmetabolism 
before onset of BD as levels of insulin resistance and rates 
of metS and their individual components did not differ 
from healthy individuals. Nonetheless, patients with BD 
and their unaffected first-degree relatives neither dif-
fer in prevalence of metS nor in levels of insulin resist-
ance from patients with BD, thus we may possibly have 
overseen a true difference between our modest sample 
size of unaffected relatives and healthy individuals. Unaf-
fected first-degree relatives had smoking prevalence at 
the same level as the Danish general population (SST 
2017) and with respect to metS, where smoking is known 
to be a major predictor (Sun et al. 2012), the unaffected 
relatives could possibly be representative of the general 
population. Nonetheless, whereas the healthy individu-
als possibly were super healthy indicated by higher edu-
cation- and activity level than the patients with BD and 
lower smoking prevalence than the Danish general popu-
lation, the unaffected first-degree relatives may possibly 
be less healthy than the general population due to their 
psychiatric dispositions and consequently would not be a 
valid control group.
Strengths and limitations
Advantages of the study include thoroughly assessment 
of a relatively large group of well-characterized patients 
with newly diagnosed BD and a group of their unaf-
fected first-degree relatives. Further, our study profited 
from a high degree of standardization (e.g., blood sam-
pling time, collection and analyses) at the same day  as 
clinical and psychiatric evaluation. Most of our patients 
with BD (81.1%) were diagnosed within the preceding 
year and the maximum time with diagnosis was 7 years. 
The average delay in diagnosis of 5 years and illness dura-
tion (time from first mood episode) of 10 years accords 
with prior findings (Kessler et al. 2007; Baldessarini et al. 
2007) and further illustrates the challenge of recruiting 
patients early in their course of illness due to the known 
diagnostic delay (Baldessarini et al. 2007).
Several limitations of our study should be considered. 
First, the sample size of unaffected relatives was mod-
erate (n = 50) due to three major reasons; (1) missing 
consent from patients to contact their relatives, (2) unaf-
fected relatives having a major psychiatric illness them-
selves and (3) lack of unaffected first-degree relatives 
satisfying the age range criteria (15–40  years). Due to 
this limited sample of healthy relatives, we were not able 
to include the measurements of sleep disturbances and 
physical activity in our fully adjusted analyses comparing 
metS and insulin resistance between groups. However, 
since there were no statistically significant differences 
between groups in the models including smoking status 
and alcohol intake, we find it unlikely, that the addition 
of sleep disturbances and physical activity measurements 
would have changed the results. Second, due to the 
cross-sectional study design, we cannot draw final con-
clusions regarding dysmetabolism before BD based on 
the findings in unaffected relatives of patients with BD, 
as the majority proportion of these will not develop BD. 
Currently we are expanding our study cohort in the lon-
gitudinal BIO study (Kessing et  al. 2017), and following 
participants prospectively, including through onset of ill-
ness, will enhance our knowledge about dysmetabolism 
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before onset of BD. Third, in contrast to well-established 
evidence we did not find association between antipsy-
chotics and metS and insulin resistance, respectively 
(Vancampfort et  al. 2013; Correll et  al. 2008; Burghardt 
et  al. 2018), however, we found an association between 
receiving psychotropics with metabolic adverse effects 
and insulin resistance. Further, lithium was also observed 
associated with insulin resistance. Caution in interpreting 
these findings should be made due to our categorization 
of treatment. Thus, our use of dichotomous treatment 
categories does not account for neither medication dose 
nor duration of treatment. Further, the concurrent treat-
ment with multiple medication types reduces or may 
even eliminate the possibility to identify an isolated effect 
of one treatment category. We may therefore not fully 
capture the true effect of psychotropic medication on 
metabolism in the present study. However, using the vari-
able of receiving psychotropics with metabolic adverse 
effects may possibly yield the most valid analysis of psy-
chotropic medication in the present study. Nonetheless, 
our findings should be interpreted with caution and we 
cannot exclude the possibility that receiving psychotrop-
ics with metabolic adverse effects is the main driver of 
the identified higher metS prevalence and insulin resist-
ance level in patients with BD compared with heatlhy 
individuals. Fourth, we included blood donors recruited 
in the Blood Bank at Rigshospitalet as healthy individu-
als. Blood donors may in some respects be regarded as 
super healthy individuals, and in our sample they had a 
longer education level, which is known to increase overall 
health (Golding et al. 2013) and they had a lower preva-
lence of smoking than the general population (SST 2017). 
Contrary to our expectations, the healthy individuals had 
higher systolic blood pressure and a higher alcohol intake 
than the patients with BD.
Conclusions
Our findings of higher prevalence of metS and elevated 
insulin resistance levels in patients with newly diagnosed 
BD compared with healthy individuals highlight the piv-
otal role of early individualized prevention strategies 
targeted against smoking, overweight, dyslipidemia and 
dysglycemia in this population. Notably, smoking was 
highly prevalent in patients with newly diagnosed BD 
and—to a lesser degree—in their unaffected first-degree 
relatives. The well-established connection between 
smoking and metS indicate that smoking cessation is 
highly relevant in these populations. Further, our findings 
suggest that the high prevalence of smoking in our popu-
lation of patients with BD was an important driver of the 
identified higher risk of metS. Similarly, central obesity 
was strongly associated with insulin resistance in patients 
with BD and found specifically in female patients newly 
diagnosed with BD. The major CVD risk accompanying 
central obesity further highlight the importance of main-
taining a healthy fat distribution and intervening against 
central obesity from time of diagnosing BD. Prevent-
ing the development of metS, type 2 diabetes and CVD 
may diminish the risk of premature death and a chronic, 
disabling illness course in patients with BD. Clinically, it 
should be considered to include assessment of metS and 
insulin resistance aiming to prevent or identify metabolic 
diseases in patients with BD from the time of diagnosis.
Significant outcomes
Patients with newly diagnosed bipolar disorder but 
not their unaffected first-degree relatives had higher 
rates of metabolic syndrome and insulin resistance 
compared with healthy individuals.
A larger waist circumference, more dyslipidemia 
and higher levels of fasting glucose and insulin were 
observed in patients with bipolar disorder compared 
with matched healthy individuals.
Assessment of the individual components of the 
metabolic syndrome, insulin resistance and smoking 
from time of diagnosis should be considered to initi-
ate adequate and early care reducing the risk of car-
diovascular disease and premature death.
Limitations
The sample size of unaffected first-degree relatives 
was modest.
Our categorization of psychotropic medication vari-
ables may not capture the true effect of psychotropic 
medication.
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